Notice Santécom: 127560
Nivolumab and pembrolizumab are two monoclonal antibodies indicated for the treatment of several cancers. Several dosing regimens are proposed in the Canadian product monographs for these drugs, specifically, a choice between weight-based doses and fixed doses. Recently, the nivolumab and pembrolizumab product monographs also proposed higher doses administered at less frequent intervals.
The dosing decision support tool developed will serve to facilitate the prescribing of these drugs by reducing the confusion due to the multitude of dosage regimens proposed in the product monographs. The few points included in the tool for certain specific populations are important considerations when managing and following these patients.